Akorn Company Profile (NASDAQ:AKRX)

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) announced its earnings results on Thursday, August, 4th. The company reported $0.58 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.03. The firm had revenue of $280.70 million for the quarter, compared to the consensus estimate of $272.99 million. Akorn had a return on equity of 30.32% and a net margin of 16.64%. The business's revenue was up 27.1% compared to the same quarter last year. View Akorn's Earnings History.

14 brokers have issued 1 year price targets for Akorn's shares. Their predictions range from $20.00 to $45.00. On average, they expect Akorn's share price to reach $31.20 in the next twelve months. View Analyst Ratings for Akorn.

Here are some recent quotes from research analysts about Akorn stock:

• 1. According to Zacks Investment Research, "Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services. " (5/8/2017)
• 2. Royal Bank Of Canada analysts commented, "We now see two major hurdles lifted (i) a much needed reset on 2017 EPS and (ii) greater comfort on new approvals from Decatur. From here, debate will move to whether there is enough new launch revenue to offset erosion and drive growth beyond 2017. Story is de-risked meaningfully but we are still struggling to find growth off lower base. Target down to $21... Leading into 4Q we have been concerned that Street numbers for 2017 were meaningfully too high and that new approvals were not coming from the Decatur facility. First time 2017 guidance of $1.53 to $1.72 should re-set the Street's $2.17, lowering the bar for this year, and last night's announced approvals out of Decatur assuaged concerns around facility risk. In other words, two major concerns around this stock have now been removed. We have updated our model and our 2017-19E EPS move roughly $0.30 lower but still show little growth at $1.61, $1.64 and $1.69 (but we think guidance is reasonable). The re-set reduced risk but pushes valuation to 9.3x our 2018E EBITDA which is not necessarily inexpensive against the limited growth in our model." (3/2/2017)

Akorn saw a decline in short interest in the month of May. As of May 15th, there was short interest totalling 7,297,197 shares, a decline of 17.4% from the April 28th total of 8,836,773 shares. Based on an average daily volume of 3,708,761 shares, the short-interest ratio is presently 2.0 days. Currently, 8.4% of the company's stock are short sold.

Some companies that are related to Akorn include Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO), Catalent (CTLT), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Theravance Biopharma (TBPH), Horizon Pharma PLC (HZNP), Pacira Pharmaceuticals (PCRX), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Innoviva (INVA), Impax Laboratories (IPXL), Amphastar Pharmaceuticals (AMPH), Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN) and Teligent (TLGT).

Akorn's management team includes the folowing people:

• John N. Kapoor Ph.D., Chairman of the Board
• Rajat Rai, Chief Executive Officer
• Duane A. Portwood, Chief Financial Officer, Executive Vice President
• Bruce Kutinsky Ph.D., Chief Operating Officer
• Joseph P. Bonaccorsi, Executive Vice President, General Counsel, Secretary
• Jonathon Kafer, Executive Vice President - Sales and Marketing
• Steven Joseph Lichter, Executive Vice President - Pharmaceutical Operations
• Randall E. Pollard, Senior Vice President, Chief Accounting Officer, Corporate Controller
• Brian Tambi, Director
• Kenneth S. Abramowitz, Independent Director

Akorn's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include KAPOOR JOHN N (25.30%), BlackRock Inc. (0.00%), Paulson & CO. Inc. (6.74%), Vanguard Group Inc. (0.00%), William Blair Investment Management LLC (0.00%) and FMR LLC (0.00%). Company insiders that own Akorn stock include Alan D Weinstein, Bruce Kutinsky, Joseph Bonaccorsi, Kenneth Abramowitz and Ronald M Johnson. View Institutional Ownership Trends for Akorn.

Akorn's stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Janus Capital Management LLC, Alliancebernstein L.P., Morgan Stanley, Paulson & CO. Inc., Summit Creek Advisors LLC, TIAA CREF Investment Management LLC and Snow Capital Management LP. View Insider Buying and Selling for Akorn.

Akorn's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Columbia Wanger Asset Management LLC, FMR LLC, Fosun International Ltd, Thornburg Investment Management Inc., LSV Asset Management, William Blair Investment Management LLC and Blue Jay Capital Management LLC. View Insider Buying and Selling for Akorn.

Shares of Akorn can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Akorn stock can currently be purchased for approximately $33.53.